💉 GLP-1 Market Boom Analysis (2023-2030)
Report ID: MKI-GLP1-2026-001 | Release Date: July 2026
Coverage: GLP-1 receptor agonist global sales data, indication expansion, competitive landscape
1. GLP-1 Market Panorama
GLP-1 receptor agonists (GLP-1 RAs) have become one of the fastest-growing drug categories in global pharmaceutical history. In 2024, GLP-1 drug global sales surpassed $36B, accounting for 55% of the total peptide market, projected to exceed $65B+ by 2028.
Market Milestones
- 2023: Semaglutide annual sales $21.2B, surpassing Keytruda as the world's best-selling drug
- 2024: Tirzepatide obesity indication (Zepbound) volume ramp, full-year sales $11.5B
- 2025E: Oral semaglutide sales expected to break $3.0B
2. Mechanism of Action and Product Evolution
2.1 GLP-1/GIP Dual-Target Mechanism
| Target Combination |
Representative Drug |
Company |
Approval Year |
Weight Loss (vs Placebo) |
| GLP-1 mono-target |
Semaglutide |
Novo Nordisk |
2017 (T2D) / 2021 (Obesity) |
-15% @ 68 weeks |
| GIP/GLP-1 dual-target |
Tirzepatide |
Eli Lilly |
2022 (T2D) / 2023 (Obesity) |
-22.5% @ 72 weeks |
| GCG/GLP-1 dual-target |
Mazdutide |
Innovent Biologics |
NDA under review |
-15.4% @ 48 weeks |
| GIP/GLP-1/GCG triple-target |
Retatrutide |
Eli Lilly |
Phase III ongoing |
-24.2% @ 48 weeks (Phase II) |
| Oral GLP-1 |
Rybelsus (semaglutide) |
Novo Nordisk |
2019 (T2D) |
-5.4% @ 26 weeks (glycemic) |
| Parameter |
Daily Injection |
Weekly Injection |
Daily Oral |
Advantage |
| Compliance |
Low |
High |
Medium |
Weekly formulation has highest compliance |
| Blood Drug Fluctuation |
Large |
Stable |
Small |
Weekly formulation has low peak-to-trough ratio |
| Dosage Frequency |
1x/day |
1x/week |
1x/day |
Weekly: 52 injections/year vs 365 |
| Bioavailability |
100% |
~55% |
~1% |
Oral formulation absorption rate extremely low |
3. Global Sales Data Analysis
3.1 Major GLP-1 Drug Global Sales (2023-2025E)
| Drug |
Brand Name |
Company |
2023 ($B) |
2024 ($B) |
2025E ($B) |
CAGR |
| Semaglutide |
Ozempic |
Novo Nordisk |
$9.6 |
$12.8 |
$15.5 |
+27% |
| Semaglutide |
Wegovy |
Novo Nordisk |
$4.5 |
$8.4 |
$12.0 |
+63% |
| Semaglutide Oral |
Rybelsus |
Novo Nordisk |
$2.3 |
$2.8 |
$3.5 |
+23% |
| Tirzepatide |
Mounjaro |
Eli Lilly |
$5.2 |
$8.5 |
$12.0 |
+52% |
| Tirzepatide |
Zepbound |
Eli Lilly |
$0.2 |
$3.0 |
$7.5 |
— |
| Dulaglutide |
Trulicity |
Eli Lilly |
$6.3 |
$5.5 |
$4.5 |
-15% |
| Liraglutide |
Victoza/Saxenda |
Novo Nordisk |
$1.8 |
$1.5 |
$1.2 |
-18% |
| Total |
— |
— |
$29.9 |
$42.5 |
$56.2 |
+37% |
Key Findings
Semaglutide series (Ozempic+Wegovy+Rybelsus) combined 2024 sales of approximately $24B, accounting for 57% of the total GLP-1 market. Tirzepatide series (Mounjaro+Zepbound) combined 2024 sales of $11.5B, accounting for 27%. The two giants together hold 84%.
3.2 China GLP-1 Market Size
| Year |
China GLP-1 Market (¥B) |
YoY Growth |
Leading Products |
| 2020 |
¥3.8 |
— |
Liraglutide, Dulaglutide |
| 2021 |
¥5.2 |
+36.8% |
Dulaglutide included in medical insurance |
| 2022 |
¥8.5 |
+63.5% |
Semaglutide included in medical insurance |
| 2023 |
¥13.8 |
+62.4% |
Semaglutide, Liraglutide |
| 2024 |
¥19.5 |
+41.3% |
Semaglutide, Tirzepatide |
| 2025E |
¥28.0 |
+43.6% |
Domestic GLP-1 + imported dual engine |
4. Indication Expansion Map
GLP-1 drugs are evolving from simple glucose-lowering agents toward multi-functional drugs for various cardiometabolic diseases:
4.1 Approved and Developing Indications
| Indication |
Semaglutide |
Tirzepatide |
Clinical Evidence Strength |
| Type 2 Diabetes (T2D) |
✅ Approved |
✅ Approved |
★★★★★ |
| Obesity/Overweight |
✅ Approved |
✅ Approved |
★★★★★ |
| Cardiovascular Disease (CVD) |
✅ SELECT positive |
⭕ Phase III |
★★★★☆ |
| Chronic Kidney Disease (CKD) |
✅ FLOW positive |
⭕ Phase III |
★★★★☆ |
| Non-Alcoholic Steatohepatitis (MASH) |
⭕ Phase III |
⭕ Phase III |
★★★☆☆ |
| Heart Failure with Preserved Ejection Fraction (HFpEF) |
✅ STEP-HFpEF positive |
⭕ Phase II |
★★★★☆ |
| Alzheimer's Disease (AD) |
⭕ Phase II |
⭕ Phase II |
★★☆☆☆ |
| Obstructive Sleep Apnea (OSA) |
✅ SURMOUNT-OSA positive |
✅ Approved (2025) |
★★★★☆ |
| Peripheral Artery Disease (PAD) |
⭕ Phase II |
— |
★★☆☆☆ |
4.2 Indication Market Size Increment
| Indication Expansion |
Corresponding New Patient Population (Global) |
2028E Potential New Market ($B) |
| T2D (covered) |
540 million |
$35 (existing) |
| Obesity (covered) |
890 million |
$50 (fast growing) |
| CVD |
520 million (CVD history) |
$12-15 |
| CKD |
850 million (CKD) |
$8-10 |
| MASH |
110 million (advanced MASH) |
$5-8 |
| HFpEF |
32 million |
$3-5 |
| OSA |
940 million (global OSA patients) |
$3-5 |
| AD |
55 million |
$2-5 (high uncertainty) |
5. China GLP-1 R&D Pipeline
5.1 Domestic GLP-1 Drug Candidates in Development
| Company |
Drug Code/Name |
Target |
Indication |
Current Phase |
| Innovent Biologics |
Mazdutide (IBI362) |
GCG/GLP-1 |
T2D+Obesity |
NDA |
| Hengrui Medicine |
Noliglipin (HR170331) |
GLP-1 |
T2D+Obesity |
Phase III |
| Gan & Lee Pharma |
GZR18 |
GLP-1 |
T2D+Obesity |
Phase III |
| Changshan Pharma |
Ebnbapitide |
GLP-1 |
T2D |
Phase III |
| Hansoh Pharma |
PEG-Loxenatide |
GLP-1 |
T2D |
Marketed |
| Renhui Biotech |
Benaglutide |
GLP-1 (human) |
T2D+Obesity |
Marketed (obesity approved) |
| Hybio Pharma |
Liraglutide generic |
GLP-1 |
T2D |
Approved |
| Jiuyuan Gene |
Semaglutide generic |
GLP-1 |
T2D |
Phase III |
| Livzon Group |
Semaglutide generic |
GLP-1 |
T2D |
Phase III |
| CSPC Pharma |
Semaglutide generic |
GLP-1 |
T2D |
Phase III |
5.2 China GLP-1 Market 2025-2027 Key Events
| Date |
Event |
Market Impact |
| 2025 H2 |
Mazdutide approval (expected) |
First domestic GCG/GLP-1 dual target |
| 2025 H2 |
Liraglutide generic market entry |
Price drops to ¥200-400/month |
| 2026 H1 |
Noliglipin approval (expected) |
Domestic GLP-1 mono-target |
| 2026 H1 |
Tirzepatide China obesity indication approval |
Imported dual target occupies premium market |
| 2026-2027 |
Multiple semaglutide generics launch |
Generic price war begins |
| 2027 |
Oral semaglutide China approval (expected) |
Oral GLP-1 enters China market |
6. Supply-Demand Tension and Capacity Bottlenecks
6.1 GLP-1 API Supply-Demand Gap
| Year |
Global Demand (kg) |
Global Supply (kg) |
Gap (kg) |
Capacity Utilization |
| 2023 |
6,500 |
5,800 |
700 |
89% |
| 2024 |
12,000 |
10,200 |
1,800 |
85% |
| 2025E |
20,000 |
16,000 |
4,000 |
80% |
| 2026E |
28,000 |
25,000 |
3,000 |
89% |
| 2028E |
45,000 |
45,000 |
0 |
100% |
API Bottleneck Analysis
Semaglutide API requires a solid-phase synthesis route of 45-50 chemical steps with an overall yield of only 1-3%, limiting capacity expansion. Tirzepatide's synthesis route is even more complex (60+ steps), with a single batch production cycle of up to 3-4 months. API supply has become the biggest bottleneck for GLP-1 industry development.
6.2 Major API Manufacturer Capacity
| Company |
GLP-1 API Capacity (kg/year) |
Main Varieties |
| Novo Nordisk (in-house) |
15,000 |
Semaglutide |
| Eli Lilly (in-house) |
8,000 |
Tirzepatide |
| WuXi AppTec |
3,500 |
Semaglutide, Tirzepatide |
| Sinopeptide |
2,000 |
Semaglutide API |
| Bachem (Switzerland) |
1,500 |
Multiple varieties |
| Other China CDMOs |
4,000 |
Generic API |
7. Global Sales Forecast (2024-2030)
7.1 GLP-1 Drug Global Market Size Forecast
| Year |
Market Size ($B) |
YoY Growth |
Injectable Share |
Oral Share |
Generic Share |
| 2024 |
$42.5 |
+42% |
85% |
10% |
5% |
| 2025E |
$56.2 |
+32% |
82% |
11% |
7% |
| 2026E |
$68.0 |
+21% |
78% |
13% |
9% |
| 2027E |
$78.0 |
+15% |
72% |
15% |
13% |
| 2028E |
$85.0 |
+9% |
65% |
17% |
18% |
| 2030E |
$95.0 |
— |
55% |
20% |
25% |
7.2 GLP-1 Product Category Forecast (2030E)
| Category |
2030E Market Size ($B) |
Representative Products |
| Injectable innovative drugs |
$52 |
Semaglutide, Tirzepatide, Retatrutide |
| Oral GLP-1 |
$19 |
Oral semaglutide, oral tirzepatide, Orforglipron |
| GLP-1 generics |
$24 |
Liraglutide generic, Semaglutide generic |
8. Risks and Challenges
8.1 Key Risks
| Risk Factor |
Impact Level |
Description |
| Supply-side bottleneck |
★★★★★ |
API capacity constraining market growth rate |
| Patent litigation |
★★★★☆ |
Semaglutide US patent expiration in 2026 facing challenges |
| Generic price competition |
★★★★☆ |
2026-2028 price decline 30-50% |
| Adverse event public opinion |
★★★☆☆ |
GI adverse reactions, thyroid C-cell tumor risk |
| Insurance coverage limitations |
★★★☆☆ |
Obesity drug insurance coverage insufficient |
Conclusion
The GLP-1 market is experiencing the hottest pharmaceutical market growth cycle in history. The global market reached $42.5B in 2024 and is expected to surpass $95B by 2030. Indications have expanded from a T2D single track to obesity, CVD, CKD, MASH, and other major therapeutic areas, providing sustained growth momentum. API capacity bottlenecks and the explosion of China's market represent the two most important structural opportunities for Chinese companies today.
Data Sources
This report data is based on Novo Nordisk and Eli Lilly annual reports (2023-2024), Evaluate Pharma, Frost & Sullivan, Yaozhi.com, and other publicly available channels. GLP-1 related industry data compiled and analyzed by SENO Biotechnology Industry Research Institute.
GLP-1 API Supply Inquiries → Contact SENO Biotechnology. SENO Biotechnology professionally provides semaglutide, tirzepatide, and other GLP-1 APIs along with peptide CDMO services, supporting stable development of the global GLP-1 supply chain.